Wenying Yu Selected Research

Therapeutics

5/2021	Retraction Note to: A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
8/2020	Discovery of bazedoxifene analogues targeting glycoprotein 130.
5/2020	LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
7/2019	Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors.
1/2019	SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer.
10/2018	A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
11/2017	Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
1/2017	Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules.
11/2016	Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.
3/2016	A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wenying Yu Research Topics

Disease

24	Neoplasms (Cancer) 01/2024 - 05/2011
4	Breast Neoplasms (Breast Cancer) 10/2021 - 11/2016
3	Triple Negative Breast Neoplasms 05/2021 - 10/2018
3	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2020
2	Lung Neoplasms (Lung Cancer) 01/2024 - 01/2021
2	Hepatocellular Carcinoma (Hepatoma) 08/2023 - 05/2011
2	Hypoxia (Hypoxemia) 04/2022 - 01/2021
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 01/2020
2	Colonic Neoplasms (Colon Cancer) 12/2021 - 03/2016
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 01/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2002
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 01/2019
1	COVID-19 01/2023
1	Drug-Related Side Effects and Adverse Reactions 12/2022
1	Starvation 04/2022
1	Leukemia 01/2022
1	Carcinoma (Carcinomatosis) 01/2022
1	Adenocarcinoma 01/2022
1	Acute Lung Injury 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Pulmonary Edema 01/2022
1	Human Influenza (Influenza) 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Carcinogenesis 10/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Bites and Stings (Sting) 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Hyperplasia 01/2021
1	Infections 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 05/2015

Drug/Important Bio-Agent (IBA)

7	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 10/2021 - 05/2011
4	Proteins (Proteins, Gene)FDA Link 10/2023 - 01/2021
3	Liposomes (Liposome)IBA 01/2024 - 12/2021
3	cryptotanshinoneIBA 05/2021 - 10/2018
3	Interleukin-6 (Interleukin 6)IBA 03/2016 - 05/2011
2	Therapeutic UsesIBA 08/2023 - 11/2022
2	ProdrugsIBA 08/2023 - 12/2019
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2020
2	LipopolysaccharidesIBA 01/2022 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2011
2	CytokinesIBA 01/2021 - 05/2011
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021 - 07/2020
2	InterferonsIBA 01/2021 - 02/2015
1	tetrandrineIBA 01/2024
1	BenzylisoquinolinesIBA 01/2024
1	AlkaloidsIBA 01/2024
1	snake venom protein C activatorIBA 10/2023
1	ArtesunateIBA 08/2023
1	Arsenic Trioxide (Trisenox)FDA Link 08/2023
1	Antineoplastic Agents (Antineoplastics)IBA 08/2023
1	BNT162 VaccineIBA 01/2023
1	Nanoparticle Drug Delivery SystemIBA 12/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 11/2022
1	tetracarboxyphenylporphineIBA 11/2022
1	Photosensitizing Agents (Photosensitizers)IBA 11/2022
1	Sucrose (Saccharose)IBA 04/2022
1	ethyleneIBA 04/2022
1	Protein Kinases (Protein Kinase)IBA 04/2022
1	Oxygen (Dioxygen)IBA 04/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	N-benzoylphenylalanylphenylalinol acetateIBA 01/2022
1	Polysaccharides (Glycans)IBA 01/2022
1	Peroxidase (Myeloperoxidase)IBA 01/2022
1	oridoninIBA 12/2021
1	Drug CombinationsIBA 10/2021
1	Histone Deacetylases (Histone Deacetylase)IBA 10/2021
1	Histone Deacetylase InhibitorsIBA 10/2021
1	Cyclic AMP (AMP, Cyclic)IBA 01/2021
1	sacubitrilIBA 01/2021
1	GMP synthase (glutamine-hydrolyzing)IBA 01/2021
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021
1	Gefitinib (Iressa)FDA Link 01/2021
1	LBQ657IBA 01/2021
1	Alcian BlueIBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	Interferon Type IIBA 01/2021
1	Periodic AcidIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	SmokeIBA 01/2021
1	Transient Receptor Potential ChannelsIBA 01/2021
1	Phenobarbital (Luminal)FDA Link 05/2020
1	Circular RNAIBA 01/2020
1	Etoposide (VP 16)FDA LinkGeneric 12/2019
1	indacaterolIBA 01/2019
1	RNA Splicing FactorsIBA 01/2019
1	Indicators and Reagents (Reagents)IBA 11/2017
1	Small Interfering RNA (siRNA)IBA 11/2017
1	Leucyl Aminopeptidase (Peptidase S)IBA 11/2017
1	Peptide Hydrolases (Proteases)FDA Link 11/2017
1	CurcuminIBA 11/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	Tacrine (Cognex)FDA Link 05/2015
1	Monoamine Oxidase (MAO)IBA 05/2015
1	Cholinesterases (Cholinesterase)IBA 05/2015
1	coumarinIBA 05/2015
1	Peptides (Polypeptides)IBA 02/2015

Therapy/Procedure

14	Therapeutics 05/2021 - 07/2011
3	Drug Therapy (Chemotherapy) 01/2024 - 12/2019